There is a lack of blood biomarkers to diagnose glioblastoma (GBM) patients. This retrospective pilot study aims to determine cell-free microRNAs (cfmiRs) in plasma samples from primary and recurrent GBM patients. Thus, 142 plasma and tissue samples were analyzed using the HTG miRNA whole transcriptome assay (WTA). By combining bioinformatic analysis and receiver operating characteristic curves, we showed that cfmiR-3180-3p and cfmiR-5739 have potential utility in primary and recurrent GBM diagnosis.
- Matias A. Bustos
- Negin Rahimzadeh
- Dave S. B. Hoon